JPRN-jRCT2051230101招募中1 期
A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease
uka Kulic MD0 个研究点目标入组 210 人开始时间: 2023年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Key inclusion criteria for part 1, 2 and 3:
- •-Availability of a person (referred to as the study partner)
- •-Adequate visual and auditory acuity, in the Investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
- •-Probable mild to moderate AD dementia (consistent with National Institute on Aging-Alzheimer's Association [NIA-AA] core clinical criteria for probable AD dementia) or prodromal AD (consistent with the NIA-AA diagnostic criteria and guidelines for mild cognitive impairment due to AD)
- •-Screening Mini-Mental State Examination (MMSE) score of 18 to 28 points, inclusive, within 84 days before baseline
- •-Clinical Dementia Rating-Global Score (CDR-GS) of 0.5, 1, or 2 within 84 days before baseline
- •-Positive amyloid PET scan (cut-off: >50 Centiloid units) within 12 months before baseline
- •-In case of treatment with symptomatic AD medications, dosing regimen must be stable for at least 8 weeks prior to baseline and until randomization
- •-Agree to apolipoprotein E (APOE) genotyping
- •Inclusion criteria for Part 4:
- •-Completed the treatment period in Part 1, Part 2, or Part 3 of the study
排除标准
- •Key exclusion criteria for part1, 2 and 3:
- •-Any evidence of other relevant neurological condition, including other (non-AD) neurodegenerative and neuropsychiatric conditions, neurovascular brain disorders, seizure disorders, inflammatory and infectious disorders of the central nervous system, trauma and delirium, among several others
- •-History of hypersensitivity to biologic agents or any of the excipients in the formulation
- •-MRI exclusion criteria: >2 lacunar infarcts, any territorial infarct >1 cm^3, any white matter lesion that corresponds to an overall Fazekas score of 3 that requires at least one confluent hyperintense lesion on the fluid-attenuated inversion recovery (FLAIR) sequence, which is 20 mm or more in any dimension
- •Exclusion criteria for Part 4:
- •-Prematurely discontinued from the treatment period for study for any reason or meeting discontinuation criteria before the baseline visit of Part 4.
- •-Any drop in hemoglobin of > 20% compared to baseline or hemoglobin value below 10 g/d
研究者
相似试验
进行中（未招募）
1 期
A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s DiseaseMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856Crohn's diseaseEUCTR2018-002001-65-GBniversity of Birmingham36
进行中（未招募）
1 期
Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitisModerate to severe ulcerative colitisEUCTR2019-004090-50-ESONCOSTELLAE S.L.32
进行中（未招募）
1 期
A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s DiseaseEUCTR2005-004313-15-GBovImmune S.A.60
进行中（未招募）
1 期
A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s DiseaseModerate to Severe Active Crohn´s DiseaseEUCTR2005-004313-15-BEovImmune S.A.60
已完成
1 期
A randomized, double blind, placebo-controlled, parallel group, pilot study to assess the safety and efficacy of a therapeutic Herpes Simplex Virus-2 (HSV-2) Deoxyribonucleic Acid (DNA) vaccine in HSV-2 positive adultsACTRN12615000094572Admedus Vaccines Pty Ltd40